NeurOp
develops treatments for central nervous system disorders that includes depression, neuropathic pain, ischemia and schizophrenia... Read moreNeurOp
develops treatments for central nervous system disorders that includes depression, neuropathic pain, ischemia and schizophrenia... Read more
News
Jun 05, 2025
StreetInsider
Press Release: NeurOp : Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecule Candidates for Chronic Cough
Dec 08, 2021
MarketScreener
NeurOp: NeurOp Receives FDA Orphan Drug Designation for NP10679 for Treatment of Subarachnoid Hemorrhage
Apr 12, 2018
FinanzNachrichten
NeurOp: NeurOp, Inc.: NeurOp Initiates Phase 1 Clinical Trial of NMDA Receptor Inhibitor NP10679
Nov 25, 2017
BioPortfolio
NeurOp: NeurOp Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 15112017 Prices from USD $250
Jul 24, 2017
OTC Breaking News
NeurOp: NIH Awards NeurOp $3.5 Million to Support Phase 1 Clinical Trial of NMDA Inhibitor NP10679
Jan 06, 2017
BioPortfolio
NeurOp: NeurOp Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250
Dec 10, 2015
NEWSWIRE
Press Release: NeurOp : NeurOp, Inc - Product Pipeline Review - 2015 Applications,Vision,Research and Medical Research Report
May 12, 2015
PR-INSIDE.COM
Press Release: NeurOp : NeurOp, Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Market Study Published
Oct 05, 2014
BIOSPACE
NeurOp: Company Profile For NeurOp Corporation
Oct 03, 2014
BIOSPACE
NeurOp: NeurOp Corporation Receives Milestone Payment As Bristol-Myers Squibb Company Nominates NMDA Receptor Compound As Drug Development Candidate
NeurOp Competitors
1
2
3
4
5
6
7
8
9
10